Sensei Biotherapeutics Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
28
- Stock Symbol
-
SNSE
- Investments
-
1
- Share Price
-
$0.40
- (As of Friday Closing)
Sensei Biotherapeutics General Information
Description
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
Contact Information
Website
www.senseibio.comCorporate Office
- 1405 Research Boulevard
- Suite 125
- Rockville, MD 20850
- United States
Corporate Office
- 1405 Research Boulevard
- Suite 125
- Rockville, MD 20850
- United States
Sensei Biotherapeutics Stock Performance
As of 25-Apr-2025, Sensei Biotherapeutics’s stock price is $0.40. Its current market cap is $10.2M with 25.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.40 | $0.38 | $0.25 - $1.94 | $10.2M | 25.2M | 2.69M | -$1.20 |
Sensei Biotherapeutics Financials Summary
As of 31-Dec-2024, Sensei Biotherapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (30,206) | (30,206) | (47,944) | (62,387) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (32,017) | (32,017) | (36,981) | (49,552) |
| Net Income | (30,157) | (30,157) | (34,101) | (48,588) |
| Total Assets | 45,361 | 45,361 | 74,374 | 118,375 |
| Total Debt | 3,845 | 3,845 | 6,208 | 8,033 |
Sensei Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sensei Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Sensei Biotherapeutics Comparisons
Industry
Financing
Details
Sensei Biotherapeutics Competitors (6)
One of Sensei Biotherapeutics’s 6 competitors is Oncorus, a Formerly VC-backed company based in Andover, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Oncorus | Formerly VC-backed | Andover, MA | ||||
| Vyriad | Venture Capital-Backed | Rochester, MN | ||||
| Replimune | Formerly VC-backed | Woburn, MA | ||||
| Gritstone bio | Formerly VC-backed | Emeryville, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany |
Sensei Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Sensei Biotherapeutics Patents
Sensei Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230272082-A1 | Anti-vista antibodies and uses thereof | Pending | 09-Nov-2021 | ||
| CA-3237437-A1 | Anti-vista antibodies and uses thereof | Pending | 09-Nov-2021 | ||
| JP-2024543236-A | Anti-vista antibodies and uses thereof | Pending | 09-Nov-2021 | ||
| AU-2022386323-A1 | Anti-vista antibodies and uses thereof | Pending | 09-Nov-2021 | ||
| EP-4429769-A1 | Anti-vista antibodies and uses thereof | Pending | 09-Nov-2021 | C07K16/2827 |
Sensei Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Sensei Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Sensei Biotherapeutics Acquisitions (1)
Sensei Biotherapeutics’s most recent deal was a Merger/Acquisition with Alvaxa Biosciences. The deal was made on 19-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Alvaxa Biosciences | 19-May-2020 | Merger/Acquisition | Biotechnology |
Sensei Biotherapeutics ESG
Risk Overview
Risk Rating
Updated April, 01, 2022
36.08 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,912
Rank
Percentile
Pharmaceuticals
Industry
of 965
Rank
Percentile
Biotechnology
Subindustry
of 443
Rank
Percentile
Sensei Biotherapeutics FAQs
-
When was Sensei Biotherapeutics founded?
Sensei Biotherapeutics was founded in 1999.
-
Where is Sensei Biotherapeutics headquartered?
Sensei Biotherapeutics is headquartered in Rockville, MD.
-
What is the size of Sensei Biotherapeutics?
Sensei Biotherapeutics has 28 total employees.
-
What industry is Sensei Biotherapeutics in?
Sensei Biotherapeutics’s primary industry is Drug Discovery.
-
Is Sensei Biotherapeutics a private or public company?
Sensei Biotherapeutics is a Public company.
-
What is Sensei Biotherapeutics’s stock symbol?
The ticker symbol for Sensei Biotherapeutics is SNSE.
-
What is the current stock price of Sensei Biotherapeutics?
As of 25-Apr-2025 the stock price of Sensei Biotherapeutics is $0.40.
-
What is the current market cap of Sensei Biotherapeutics?
The current market capitalization of Sensei Biotherapeutics is $10.2M.
-
Who are Sensei Biotherapeutics’s competitors?
Oncorus, Vyriad, Replimune, Gritstone bio, and BioNTech are some of the 6 competitors of Sensei Biotherapeutics.
-
What is Sensei Biotherapeutics’s annual earnings per share (EPS)?
Sensei Biotherapeutics’s EPS for 12 months was -$1.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
